



**Solagran Limited**

Solagran Limited  
ACN 002 592 396  
98-106 Moray Street  
Melbourne, 3205  
Victoria  
Australia  
Tel 61 3 9820 2699  
Fax 61 3 9820 3155

15 April 2015

## **ASX Announcement**

### **Important United States Patent Granted for Solagran for Ropren (polyprenols), and their use in cognition, addiction and other applications**

**Melbourne, Australia:** Solagran Ltd (ASX: SLA) announces that a further key patent recently issued in the United States. This US patent protects medicinal agents, including the Company's Ropren product and other prenol formulations, used for treating certain important disease types caused by excessive activity of monoamine oxidase enzymes. Monoamine oxidases are an important family of enzymes involved in the breakdown of neurotransmitters. This new patent provides exclusivity to Solagran for the company's methods for treating related diseases, which can include Alzheimer's, Parkinson or Huntington diseases, and also for treating dependency on agents such as alcohol, nicotine and other addictive drugs.

United States Patent No. 8,952,074 is entitled "Medicinal agent for treating patients suffering from diseases caused by the monoaminooxidase excessive activity and a method for treating patients suffering from diseases caused by monoaminooxidase excessive activity". Corresponding patents are already granted in Australia and Russia, and filed in other selected jurisdictions.

Dr Vagif Soultanov, Chairman of Solagran and inventor on the patent with Solagran's Professor Viktor Roschin, said "The granting of this patent in the US is a further important event for Solagran. It establishes our proprietary position under rigorous US Patent Office examination and is an important commercial milestone which provides sufficient claims and coverage to provide exclusivity over Ropren and other products, including our methods, to treat certain important neurodegenerative diseases".

"It further validates our strategy of seeking US patent protection for our key intellectual property, despite the length of time, expense and difficulty of US patent route", Dr Soultanov added. "Combined with the recent granting of our core technology patent in the US, and the recent allowance of our additional US patent specifically for Alzheimer-type dementia applications, we will have a formidable patent portfolio in the cognition and related areas for our core Bioeffectives".

Solagran is currently in negotiations to secure distribution for products containing its proprietary Bioeffectives in selected countries, and is also preparing registration documentation for new territories.

### **Status Update of Solagran's Intellectual Property Portfolio**

Solagran Intellectual property totals 13 granted Patent Applications. Seven of these are through the Patent Cooperation Treaty (PCT) process, an international patent law treaty, and have issued in multiple jurisdictions (see table below). Two of these "PCTs" are focussed on core extraction and processing technology. The remaining five are focussed on the therapeutic use, and are variously progressing through "national phases" in Australia, European Union, USA, Canada and South East Asia. There are also an additional six non-PCT (regional) patents granted. This portfolio creates a barrier that

prevents a competitor from replicating the company's products and limits the potential therapeutic claims for competitor products.

As well as protecting Solagran's core production technology, the company's patent strategy focuses on obtaining "methods of use" and application in different areas of medicine, nutrition, skincare, animal husbandry and agriculture for Bioeffectives and other products in commercially-important therapeutic areas which are relevant to the company's research and existing data.

Solagran has an exclusive and proprietary position on all of the patents listed below, which are either owned directly, assigned to Solagran or exclusively licensed to the company.

The company also holds multiple trademarks over product and ingredient names and particularly their key tradename "Bioeffectives®", which are biologically active galenical substances obtained using specialised, patented technology that allows their isolation as balanced, synergistic complexes possessing high nutrient and therapeutic properties.

Patent Family / Technology	Australia	USA	Russia	Elsewhere
CORE TECHNOLOGICAL PATENT "Processing Vegetable Raw Materials" Protects unique extraction technology	Granted	Granted US8,969,517	Granted	Granted Latvia Canada Indonesia
CELL SAP TECHNOLOGICAL PATENT Method for producing vegetable cell sap concentrate.	Granted	Under Examination	Granted	Granted Malaysia
THERAPEUTIC USE PATENT Bioeffective R in the treatment of DEMENTIA/ALZHEIMER'S	Granted	Allowance Indicated Awaiting notification	Granted	Granted EPO Individual jurisdictions to be nominated
THERAPEUTIC USE PATENT Bioeffective I R in the treatment of ALCOHOLISM/NARCOTIC DEPENDANCE	Granted	Under Examination	Granted	Granted EPO Individual jurisdictions to be nominated
THERAPEUTIC USE PATENT Bioeffective R in the treatment of disease caused by excessive monoamineoxidase.	Granted	Granted US8,952,074	Granted	

Table: Selected key patents in Solagran's intellectual property portfolio.

### About Solagran

Solagran Ltd is a Melbourne-based biotechnology company. It manufactures and markets a range of unique, efficacious and proprietary products sourced from different species of conifer trees, targeting the fast-growing natural healthcare and nutraceutical sectors. Solagran's competitive advantage in the sector is its long history of scientific excellence, academic credibility and proprietary manufacturing innovations. The company's products range from registered pharmaceuticals, to supplements, nutraceuticals and over-the-counter products. Solagran products are marketed in Australia, Russia, Malaysia and the UAE, and additionally registered in Indonesia and Singapore, with negotiations underway to expand into new territories.

Dr. Vagif Soultanov  
Chairman  
Solagran Limited